Search Clinical Trials
Sponsor Condition of Interest |
---|
COVID-19 Vaccine Response in Chronic Respiratory Conditions
National Jewish Health
SARS-CoV Infection
The investigators will assess the antibody, T cell and B cell responses to SARS-CoV-2
vaccination before and every 3 months for 18 months after the initial vaccination or
subsequent vaccinations (boosters) in adults and children including patients with chronic
medical conditions. expand
The investigators will assess the antibody, T cell and B cell responses to SARS-CoV-2 vaccination before and every 3 months for 18 months after the initial vaccination or subsequent vaccinations (boosters) in adults and children including patients with chronic medical conditions. Type: Observational Start Date: Feb 2021 |
Point-of-care Lung Ultrasound (POCUS)-Integrated Study of Admitted Patients With COVID-19
Olive View-UCLA Education & Research Institute
Lung Injury
ARDS
Acute Cardiac Event
Covid19
Ultrasound
This study seeks to define the ultrasound profile of patients with COVID-19, and document
the progression of these ultrasound findings to develop prognostication and clinical
decision instruments that can help guide management of patient with COVID-19. Primary
aims include the development of ARDS,... expand
This study seeks to define the ultrasound profile of patients with COVID-19, and document the progression of these ultrasound findings to develop prognostication and clinical decision instruments that can help guide management of patient with COVID-19. Primary aims include the development of ARDS, refractory hypoxemia, acute cardiac injury, pulmonary embolism, pneumothorax or death. Secondary aims include potential change in CT and plain film utilization given the use of POCUS, as well as emergency department and inpatient LOS (length of stay). Type: Observational Start Date: Nov 2020 |
PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray
Kenneth Palmer
COVID-19 Prevention
This is the first-in-human clinical study to see if a single dose of an investigational
nasal spray made from a modified plant protein called Q-Griffithsin is safe, tolerated
and acceptable for use by healthy adults 18 to 60 years of age. expand
This is the first-in-human clinical study to see if a single dose of an investigational nasal spray made from a modified plant protein called Q-Griffithsin is safe, tolerated and acceptable for use by healthy adults 18 to 60 years of age. Type: Interventional Start Date: Nov 2021 |
Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19
Patrick Robinson
Covid19
COVID-19 Pneumonia
COVID-19 Respiratory Infection
COVID-19 Acute Bronchitis
Ivermectin is currently being utilized by a number of physicians in the local area. My
objective will be to enroll these patients at the time of their evaluation for COVID-19
infection and to follow their progress through their recovery. expand
Ivermectin is currently being utilized by a number of physicians in the local area. My objective will be to enroll these patients at the time of their evaluation for COVID-19 infection and to follow their progress through their recovery. Type: Observational [Patient Registry] Start Date: May 2022 |
Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
Thomas Advanced Medical LLC
Autoimmune Diseases
Cardiovascular Disorders
Diabetes Complications
Integumentary Disease
Musculoskeletal Disorders
This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of
stem cell therapy for the treatment of various acute and chronic conditions. Clinically
observed initial findings and an extensive body of research indicate regenerative
treatments are both safe and effective for... expand
This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions. Clinically observed initial findings and an extensive body of research indicate regenerative treatments are both safe and effective for the treatment of multiple conditions. Type: Interventional Start Date: Jul 2020 |
ImmuneSense™ COVID-19 Study
Adaptive Biotechnologies
Coronavirus Disease (COVID-19)
SARS-CoV-2 Infection
Coronavirus disease is of an urgent global priority. The purpose of ImmuneSense™ COVID-19
study is to evaluate the clinical performance and to provide data for clinical validation
for the T-Detect™ SARS-CoV-2 (previously referred to as immunoSEQ Dx SARS-CoV-2) Assay in
support of Adaptive's Emergency... expand
Coronavirus disease is of an urgent global priority. The purpose of ImmuneSense™ COVID-19 study is to evaluate the clinical performance and to provide data for clinical validation for the T-Detect™ SARS-CoV-2 (previously referred to as immunoSEQ Dx SARS-CoV-2) Assay in support of Adaptive's Emergency Use Authorization (EUA) request for T-Detect™ SARS-CoV-2 and secondary aims. This assay is intended to detect immune response to the virus that causes coronavirus disease (COVID-19), SARS-CoV-2. This is critically important because the immune system may be able to tell us important information about how our own bodies detect and respond to the disease that current tests cannot. Type: Observational Start Date: Oct 2020 |
Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19
Metro Infectious Disease Consultants
COVID-19
This study will provide investigational convalescent plasma for patients infected with
the SARS-CoV-2 with mild to moderate symptoms who meet inclusion criteria as judged by
physician evaluation. expand
This study will provide investigational convalescent plasma for patients infected with the SARS-CoV-2 with mild to moderate symptoms who meet inclusion criteria as judged by physician evaluation. Type: Interventional Start Date: Aug 2020 |
A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).
Tufts Medical Center
COVID-19
The investigators hypothesize that early institution of TNFα inhibitor therapy in
patients with severe COVID-19 infections will prevent further clinical deterioration and
reduce the need for advanced cardiorespiratory support and early mortality. To address
this hypothesis, a prospective, single center,... expand
The investigators hypothesize that early institution of TNFα inhibitor therapy in patients with severe COVID-19 infections will prevent further clinical deterioration and reduce the need for advanced cardiorespiratory support and early mortality. To address this hypothesis, a prospective, single center, phase 2 trial is proposed to assess the efficacy of infliximab or infliximab-abda in hospitalized adult patients with severe or critical COVID-19. Observations from this study will inform the conduct of prospective randomized controlled studies to follow. Type: Interventional Start Date: Jun 2020 |
Myeloproliferative Neoplasms (MPN) and COVID-19
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Myeloproliferative Neoplasm
COVID
An increased risk of both venous and arterial thromboembolism was noted in reports from
SARS-CoV-2-infected patients in China and has been confirmed in autopsy findings from
patients who experienced sudden death. Myeloproliferative Neoplasms (MPNs), which
encompass polycythemia vera, essential thrombocythemia... expand
An increased risk of both venous and arterial thromboembolism was noted in reports from SARS-CoV-2-infected patients in China and has been confirmed in autopsy findings from patients who experienced sudden death. Myeloproliferative Neoplasms (MPNs), which encompass polycythemia vera, essential thrombocythemia and primary myelofibrosis, are thrombophilic disorders with a natural propensity to thrombosis that is fuelled by the intrinsic activation of inflammatory cytokines. It therefore follows that an underlying diagnosis of MPN may increase the risk of worse clinical outcomes and death during periods of active Covid-19 disease. This ambispective, observational study aims to elucidate the key factors which affect the clinical course of patients with MPN who develop Covid-19 disease. Type: Observational Start Date: May 2020 |
MSCs in COVID-19 ARDS
Icahn School of Medicine at Mount Sinai
Mesenchymal Stromal Cells
Remestemcel-L
Acute Respiratory Distress Syndrome
COVID
The mortality rate in SARS-CoV-2-related severe ARDS is high despite treatment with
antivirals, glucocorticoids, immunoglobulins, and ventilation. Preclinical and clinical
evidence indicate that MSCs migrate to the lung and respond to the pro-inflammatory lung
environment by releasing anti-inflammatory... expand
The mortality rate in SARS-CoV-2-related severe ARDS is high despite treatment with antivirals, glucocorticoids, immunoglobulins, and ventilation. Preclinical and clinical evidence indicate that MSCs migrate to the lung and respond to the pro-inflammatory lung environment by releasing anti-inflammatory factors reducing the proliferation of pro-inflammatory cytokines while modulating regulatory T cells and macrophages to promote resolution of inflammation. Therefore, MSCs may have the potential to increase survival in management of COVID-19 induced ARDS. The primary objective of this phase 3 trial is to evaluate the efficacy and safety of the addition of the mesenchymal stromal cell (MSC) remestemcel-L plus standard of care compared to placebo plus standard of care in patients with acute respiratory distress syndrome (ARDS) due to SARS-CoV-2. The secondary objective is to assess the impact of MSCs on inflammatory biomarkers. Type: Interventional Start Date: Apr 2020 |
Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia
Masonic Cancer Center, University of Minnesota
COVID-19
This is a Phase I study with the primary objective of identifying the maximum tolerated
dose (MTD) of FT516 using 3 dose-escalation strategies (number of doses and cell dose)
for the treatment of coronavirus disease 2019 (COVID-19). This study provides initial
estimates of safety and efficacy based... expand
This is a Phase I study with the primary objective of identifying the maximum tolerated dose (MTD) of FT516 using 3 dose-escalation strategies (number of doses and cell dose) for the treatment of coronavirus disease 2019 (COVID-19). This study provides initial estimates of safety and efficacy based on stable respiratory function, as well as, determining the feasibility for full-scale studies designed both for efficacy and safety. Type: Interventional Start Date: May 2020 |
Plasma Adsorption in Patients With Confirmed COVID-19
Marker Therapeutics AG
Respiratory Failure
ARDS
To characterize the ability of the D2000 Cartridge in combination with the Optia SPD
Protocol to reduce the morbidity and mortality associated with SARS-CoV-2 infection in
patients admitted to the ICU. expand
To characterize the ability of the D2000 Cartridge in combination with the Optia SPD Protocol to reduce the morbidity and mortality associated with SARS-CoV-2 infection in patients admitted to the ICU. Type: Interventional Start Date: May 2020 |
Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers
Inovio Pharmaceuticals
Coronavirus Infection
This is an open-label trial to evaluate the safety, tolerability and immunological
profile of INO-4800 administered by intradermal (ID) injection followed by
electroporation (EP) using CELLECTRA® 2000 device in healthy adult volunteers. expand
This is an open-label trial to evaluate the safety, tolerability and immunological profile of INO-4800 administered by intradermal (ID) injection followed by electroporation (EP) using CELLECTRA® 2000 device in healthy adult volunteers. Type: Interventional Start Date: Apr 2020 |
Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19
Intermountain Health Care, Inc.
COVID-19
This study will compare two drugs (hydroxychloroquine and azithromycin) to see if
hydroxychloroquine is better than azithromycin in treating hospitalized patients with
suspected or confirmed COVID-19. expand
This study will compare two drugs (hydroxychloroquine and azithromycin) to see if hydroxychloroquine is better than azithromycin in treating hospitalized patients with suspected or confirmed COVID-19. Type: Interventional Start Date: Mar 2020 |
A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor...
BioCytics, Inc.
Solid Tumor, Adult
Healthy Donors
COVID-19 Donors
Primary Objective:
This is a study to investigate the feasibility of harvesting, expanding, and selecting T
lymphocytes from cancer patients and healthy volunteers. The preliminary objective of
this study is aimed at selecting PD-1+ and CTLA4+ T cells and other cellular fractions
from peripheral... expand
Primary Objective: This is a study to investigate the feasibility of harvesting, expanding, and selecting T lymphocytes from cancer patients and healthy volunteers. The preliminary objective of this study is aimed at selecting PD-1+ and CTLA4+ T cells and other cellular fractions from peripheral blood of cancer patients and healthy volunteers by using specific conjugated antibodies, evaluating their functional ex vivo anti-tumor cytotoxicity against targeted autologous tumor cells. Type: Observational Start Date: Nov 2007 |
The Burden of Lyme Disease (BOLD) in a Pandemic - Insights From an Online Cross-sectional and Prospective...
Dr. Daniel Cameron & Associates
COVID-19
Lyme Disease
COVID-19 Vaccine
A cross-sectional descriptive survey of the BOLD for individuals after having been ill
with COVID-19 or have taken the COVID-19 vaccine will be compared with that of
individuals who have neither been ill with COVID-19 nor taken the COVID-19 vaccine.
Individuals who have both been ill and taken the... expand
A cross-sectional descriptive survey of the BOLD for individuals after having been ill with COVID-19 or have taken the COVID-19 vaccine will be compared with that of individuals who have neither been ill with COVID-19 nor taken the COVID-19 vaccine. Individuals who have both been ill and taken the COVID-19 vaccine will be compared to identify any additive risk factors. Type: Observational Start Date: Jul 2021 |
Tolerability and Efficacy of RJX in Patients With COVID-19
Reven Pharmaceuticals, Inc.
COVID-19
Acute Respiratory Distress Syndrome
SARS-CoV-2
Hypoxemia
This study is designed as a 2-part, 2-cohort, double-blind, randomized, placebo
controlled, multicenter Phase 1/2 study to evaluate the safety, tolerability and efficacy
of RJX in patients with COVID-19. expand
This study is designed as a 2-part, 2-cohort, double-blind, randomized, placebo controlled, multicenter Phase 1/2 study to evaluate the safety, tolerability and efficacy of RJX in patients with COVID-19. Type: Interventional Start Date: Mar 2021 |
COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens...
Regeneron Pharmaceuticals
COVID-19
The primary objective of the study is to assess the virologic efficacy of
REGN10933+REGN10987 across different intravenous and subcutaneous doses compared to
placebo.
The secondary objectives of the study are:
- To evaluate additional indicators of virologic efficacy of REGN10933+REGN10987... expand
The primary objective of the study is to assess the virologic efficacy of REGN10933+REGN10987 across different intravenous and subcutaneous doses compared to placebo. The secondary objectives of the study are: - To evaluate additional indicators of virologic efficacy of REGN10933+REGN10987 compared to placebo - To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo - To assess the concentrations of REGN10933 and REGN10987 in serum over time - To assess the immunogenicity of REGN10933 and REGN10987 Type: Interventional Start Date: Dec 2020 |
At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19
Daniel Griffin
Covid19
This is an open-label, pragmatic, single-dose study using matched controls in
participants with mild to moderate COVID-19. Participants will track for developing
symptoms while at home and upon reporting of symptoms will test for COVID-19. If positive
for COVID-19, a one-time at-home infusion of Bamlanivimab... expand
This is an open-label, pragmatic, single-dose study using matched controls in participants with mild to moderate COVID-19. Participants will track for developing symptoms while at home and upon reporting of symptoms will test for COVID-19. If positive for COVID-19, a one-time at-home infusion of Bamlanivimab (LY3819253) will be provided by Optum Infusion. Participants will then track for 28 days to assess for any additional medical care needed or if hospitalization was required. Type: Interventional Start Date: Jan 2021 |
COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy...
ImmunityBio, Inc.
COVID-19
This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is
designed to assess the safety, reactogenicity, and immunogenicity of the
hAd5-S-Fusion+N-ETSD vaccine and select a dose for future studies. expand
This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of the hAd5-S-Fusion+N-ETSD vaccine and select a dose for future studies. Type: Interventional Start Date: Oct 2020 |
Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant...
Hengenix Biotech Inc
COVID 19
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Clinical Study to
Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity
of HLX71 in Healthy Adult Subjects expand
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 in Healthy Adult Subjects Type: Interventional Start Date: Apr 2021 |
Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS)
University of Alabama at Birmingham
ARDS
Covid19
Acute Hypoxemic Respiratory Failure
Prone positioning is one of the few therapies known to improve mortality in ARDS.
Traditionally, patients are proned for 16 hours per 24 hour period. Some retrospective
data suggests improvement may persist beyond 16 hours. We aim to perform a pilot study
comparing traditional prone positioning to... expand
Prone positioning is one of the few therapies known to improve mortality in ARDS. Traditionally, patients are proned for 16 hours per 24 hour period. Some retrospective data suggests improvement may persist beyond 16 hours. We aim to perform a pilot study comparing traditional prone positioning to prolonged prone positioning in patients with COVID-induced ARDS. Type: Interventional Start Date: Nov 2020 |
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
Galera Therapeutics, Inc.
Covid19
SARS-CoV-2 Infection
A Trial of GC4419 in Patients with Critical Illness due to COVID-19 expand
A Trial of GC4419 in Patients with Critical Illness due to COVID-19 Type: Interventional Start Date: Sep 2020 |
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
University of Minnesota
COVID
COVID-19
SARS-CoV-2
SARS (Severe Acute Respiratory Syndrome)
This protocol will serve as a platform for assessing treatments for adult patients
hospitalized for medical management of COVID-19 without related serious end-organ
failure. Trials will involve sites around the world strategically chosen to ensure rapid
enrollment. This trial will compare hyperimmune... expand
This protocol will serve as a platform for assessing treatments for adult patients hospitalized for medical management of COVID-19 without related serious end-organ failure. Trials will involve sites around the world strategically chosen to ensure rapid enrollment. This trial will compare hyperimmune intravenous immunoglobulin (hIVIG) with matched placebo, when added to standard of care (SOC), for preventing further disease progression and mortality related to COVID-19. SOC will include remdesivir unless it is contraindicated for an individual patient. Type: Interventional Start Date: Oct 2020 |
TD-0903 for ALI Associated With COVID-19
Theravance Biopharma
Acute Lung Injury (ALI) Associated With COVID-19
Lung Inflammation Associated With COVID-19
This Phase 2 study will evaluate the efficacy, safety, pharmacodynamics and
pharmacokinetics of inhaled TD-0903 compared with a matching placebo in combination with
standard of care (SOC) in hospitalized patients with confirmed COVID-19 associated acute
lung injury and impaired oxygenation. expand
This Phase 2 study will evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of inhaled TD-0903 compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with confirmed COVID-19 associated acute lung injury and impaired oxygenation. Type: Interventional Start Date: Jun 2020 |
- Previous
- Next